{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for nonoxynol root_references_@count in root_references_@count (approximate match)
Status:
Investigational
Source:
NCT03963895: Phase 2 Interventional Completed End Stage Renal Disease
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT04690348: Phase 2 Interventional Recruiting Recurrent Brain Metastases
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00942799: Phase 1 Interventional Completed Solid Tumors
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Genz-644282 is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity (IC50=1.2 nM). It was in clinical development for the treatment of the solid tumors but later was discontinued.
Status:
Investigational
Source:
NCT00862888: Phase 2 Interventional Completed Erectile Dysfunction
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
PF-00446687 is the highly selective, brain-penetrant, melanocortin 4 receptor (MC4R) agonist. PF-00446687 induced partner preferences formation in females prairie voles after a 6-h cohabitation without mating. PF-00446687 had been in phase I clinical trial for the treatment of sexual function disorders.
Status:
Investigational
Source:
NCT02800590: Phase 2 Interventional Completed Colonoscopy
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
MDCO 700 (formerly ABP 700) is hypnosedative and anaesthetic agent that was being developed by The Medicines Company for the induction of general anesthesia and procedural sedation. It is a positive allosteric modulator of the GABAA receptor. It is a second generation analogue of etomidate, developed to retain etomidate's beneficial haemodynamic and respiratory profile but diminishing its suppression of the adrenocortical axis. Infusions of ABP-700 showed a dose-dependent hypnotic effect, and did not cause severe hypotension, severe respiratory depression, or adrenocortical suppression. The drug development for anaesthesia has been discontinued.
Status:
Investigational
Source:
NCT01449591: Phase 2 Interventional Completed Erythemato-telangiectatic Rosacea
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT02898779: Phase 1 Interventional Completed Malaria
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02898779: Phase 1 Interventional Completed Malaria
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01807910: Early Phase 1 Interventional Withdrawn Obesity
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT04709692: Phase 2 Interventional Completed Malaria, Falciparum
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
